Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) — Cash Flow Quality Index
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) has a Cash Flow Quality Index of -0.05x as of March 2026. Operating cash flow of $-91.25K is below net income of $1.97 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Drugs Made In America Acquisition Corp. cash flow conversion to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Drugs Made In America Acquisition Corp. Ordinary Shares Cash Flow Quality Index (2025–2025)
Historical Cash Flow Quality Index for Drugs Made In America Acquisition Corp. Ordinary Shares across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check how aggressively does Drugs Made In America Acquisition Corp. reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Drugs Made In America Acquisition Corp. Ordinary Shares (2025–2025)
Year-by-year earnings quality comparison for Drugs Made In America Acquisition Corp. Ordinary Shares. For live market cap and the full company financial profile, see DMAA company net worth.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | -0.14x | $-539.19K | $3.97 Million | — |